The Assessing Officer has proposed additions of ₹571.16 crore to Divi’s Laboratories’ income for FY23, targeting the company’s transfer pricing arrangements and other adjustments. The pharmaceutical manufacturer received the draft assessment order following what appears to be an extended review of its international transaction structures.
The company disclosed that it intends to file objections against the proposed additions. Divi’s Laboratories maintains operations across multiple jurisdictions, creating the complex web of intercompany transactions that typically draw transfer pricing scrutiny.
Draft assessments of this magnitude rarely emerge without prior correspondence between the company and tax authorities. The three-year gap between the financial year in question and the draft order suggests either a detailed audit process or disputes over documentation and benchmarking studies.
Transfer pricing cases in the pharmaceutical sector often center on intellectual property licensing, cost-sharing arrangements, and the allocation of research and development expenses across entities. Companies with significant export revenues and related-party transactions face heightened scrutiny over their pricing methodologies.
The market’s reaction proved muted, with shares closing up 2.21% at ₹6,109.55. Investors appear to be treating this as a procedural matter rather than a fundamental challenge to the company’s business model. This response suggests either confidence in the company’s documentation or experience with similar cases that ultimately settle for lesser amounts.
What remains unclear is the specific nature of the proposed adjustments. Transfer pricing orders typically break down into primary and secondary adjustments, with the latter carrying additional interest and penalty implications. The company’s disclosure does not specify whether the ₹571.16 crore figure includes these secondary adjustments.
My Boardroom Takeaway:
Audit committees should review their oversight of transfer pricing documentation and dispute management. Directors may wish to ensure that quarterly risk assessments explicitly address the quantum and timing of potential tax contingencies. A prudent approach would include regular updates on the status of ongoing assessments and the adequacy of provisions for disputed demands.